FDA Approval to Initiate a Clinical Trial for a Novel Treatment for Disc Nucleus Regeneration

Apr 28, 2009 08:00 ET
ISTO Technologies

ST. LOUIS, MO–(Marketwire – April 28, 2009) – ISTO Technologies, Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) allowing the company to proceed with a Phase I clinical study for NuQu™, a cell-based injectable formulation of juvenile chondrocytes designed to regenerate cartilage, restore disc function and relieve discogenic back pain. Research studies have shown that juvenile cartilage cells regenerate cartilage in both in vitro and in vivo environments. NuQu is intended as an early intervention treatment for patients suffering from low back pain by potentially repairing cell biology in a damaged disc, restoring health and improving function. More…